Ascendis Pharma A/s

Silence Therapeutics Gmbh

Silence Therapeutics Ag

Silence Therpeutics Ag

Pantherna Therapeutics Gmbh

Oliver Keil

Harald Rau

Ulrich Hersel

Jörg Kaufmann

Ansgar Santel

Thomas Wegge

Kennett Sprogøe

Klaus Giese

Guillaume Maitro

Joachim Zettler

Nicola Bisek

Torben Lessmann

Dirk Vetter

Nora Kaluza

Joerg Kaufmann

Kennett SprogØe

The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.

Diagnosis, prevention and treatment of diseases of the joint

Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

Carrier-linked treprostinil prodrugs

The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z&#x2014;(X-L-PG)(I), wherein Z, X, L, PGand y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.

Carrier-linked prostanoid prodrugs

The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.

Sustained release composition of prostacyclin

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I),  

Lipids, lipid complexes and use thereof

The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.

Coated lipid complexes and their use

The present invention is related to a compound according to formula (I), wherein Rand Rare each and independently selected from the group comprising alkyl; wherein m is any integer from 1 to 3 and

The present invention is related to a nucleic acid molecule and uses thereof. The nucleic acid molecule comprises a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO:1 (NM_013355).

Means for inhibiting the expression of protein kinase 3

The present invention is related to a compound according to formula (I), wherein Rand Rare each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; Ris an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y&#xc9; is a pharmaceutically acceptable anion. 

Growing community of inventors

Glienicke, Germany

Oliver Keil